Document is current
Any future updates will be listed below
-
Authors
Watabayashi, Kate K.
Bell-Brown, Ari
Kreizenbeck, Karma
Egan, Kathryn
Lyman, Gary H.
Hershman, Dawn L.
Arnold, Kathryn B.
Bansal, Aasthaa
Barlow, William E.
Sullivan, Sean D.
Ramsey, Scott D.
-
Funding
Funding for this research was provided by:
Patient-Centered Outcomes Research Institute (PCS-1402-09988, PCS-1402-09988, PCS-1402-09988, PCS-1402-09988, PCS-1402-09988, PCS-1402-09988, PCS-1402-09988, PCS-1402-09988, PCS-1402-09988, PCS-1402-09988)
National Institutes of Health and National Cancer Institute (P30 CA015704)
- License Information
-
More Information
Article History
Received: 15 December 2021
Accepted: 23 March 2022
First Online: 1 April 2022
Declarations
:
: All patients provided informed consent. Study procedures and materials were approved by the Fred Hutchinson Cancer Research Center’s institutional review board and by the institutional review boards at each enrolling site. All patient activities took place after approval by a local institutional review board (IRB) and in accordance with an assurance filed with and approved by the U.S. Department of Health and Human Services.
: Not applicable.
: SR reports consulting or advisory roles with Bayer Corporation, Bristol-Myers Squibb, AstraZeneca, Merck & Company Inc, Pfizer, Seattle Genetics, Biovica, Genentech (institution); research funding from Bayer Corporation, Bristol-Myers Squibb; and travel accommodations or expenses from Bayer Schering Pharma, Bristol-Myers Squibb, and Bayer. GL reports educational programs or consulting roles with G1 Therapeutics; Partners Healthcare; BeyondSpring; Sandoz; Squibb; Merck; Jazz Pharm; Kallyope; TEVA; Seattle Genetics and Samsung; and research funding from Amgen (Inst). The reported relationships may not relate to the subject matter of this manuscript. All other authors declare that they have no competing interests.
